Profile
Alan B. Glassberg is currently a Principal at The University of California, San Francisco.
He was previously a Director at Biogen, Inc. from 1997 to 2009 and a Director at Biogen Idec New Ventures, Inc. from 1997 to 2008.
He also held positions as a Director at IDEC Pharmaceuticals Corp., a Director at Aravive Biologics, Inc., and a Chief Medical Officer at Poniard Pharmaceuticals, Inc. Additionally, he was a Member at Bay City Capital LLC.
Glassberg holds a doctorate from the Medical University of South Carolina and an undergraduate degree from the College of Charleston.
Alan B. Glassberg active positions
| Companies | Position | Start |
|---|---|---|
The University of California, San Francisco
The University of California, San Francisco Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | 01/01/1970 |
Former positions of Alan B. Glassberg
| Companies | Position | End |
|---|---|---|
| BIOGEN INC. | Director/Board Member | 01/06/2009 |
Biogen Idec New Ventures, Inc.
Biogen Idec New Ventures, Inc. Investment ManagersFinance Biogen Idec New Ventures' strategy is to select investments in companies developing innovative human therapeutic products or technologies that will drive product discovery and development more efficiently. Their specific areas of interest are companies in Biogen Idec's current therapeutic areas of neurology, oncology and immunology/inflammation, but they also seek opportunities outside these areas that fit their strategies for longer-term growth. The firm invests at all stages of development; most of their investments are in early-stage companies. They also look for investment opportunities where they can leverage their parent's resources and scientific and development expertise to support these investments. | Director/Board Member | 31/12/2008 |
| PONIARD PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 15/03/2007 |
Aravive Biologics, Inc.
Aravive Biologics, Inc. Pharmaceuticals: MajorHealth Technology Deals with development of biopharmaceutical industry | Director/Board Member | - |
Bay City Capital LLC
Bay City Capital LLC Investment ManagersFinance Bay City Capital invests in public and private companies located across the globe. The firm focuses on a broad range of sectors and industries. It provides financing for seed, early and later stage capital transactions. The firm makes co-investments. It acts as a lead investor and takes a seat on the board of directors. | Corporate Officer/Principal | - |
Training of Alan B. Glassberg
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 9 |
|---|---|
Poniard Pharmaceuticals, Inc.
Poniard Pharmaceuticals, Inc. BiotechnologyHealth Technology Develops therapeutic biopharmaceuticals, primarily for the treatment of cancer, cardiovascular and inflammatory diseases | Health Technology |
Biogen, Inc.
Biogen, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and markets therapies for neurological and neurodegenerative diseases | Health Technology |
IDEC Pharmaceuticals Corp.
IDEC Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Discovers, develops and commercializes targeted immunotherapies for the treatment of cancer and autoimmune diseases | Health Technology |
Medical University of South Carolina
Medical University of South Carolina Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
College of Charleston
College of Charleston Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The University of California, San Francisco
The University of California, San Francisco Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Bay City Capital LLC
Bay City Capital LLC Investment ManagersFinance Bay City Capital invests in public and private companies located across the globe. The firm focuses on a broad range of sectors and industries. It provides financing for seed, early and later stage capital transactions. The firm makes co-investments. It acts as a lead investor and takes a seat on the board of directors. | Finance |
Biogen Idec New Ventures, Inc.
Biogen Idec New Ventures, Inc. Investment ManagersFinance Biogen Idec New Ventures' strategy is to select investments in companies developing innovative human therapeutic products or technologies that will drive product discovery and development more efficiently. Their specific areas of interest are companies in Biogen Idec's current therapeutic areas of neurology, oncology and immunology/inflammation, but they also seek opportunities outside these areas that fit their strategies for longer-term growth. The firm invests at all stages of development; most of their investments are in early-stage companies. They also look for investment opportunities where they can leverage their parent's resources and scientific and development expertise to support these investments. | Finance |
Aravive Biologics, Inc.
Aravive Biologics, Inc. Pharmaceuticals: MajorHealth Technology Deals with development of biopharmaceutical industry | Health Technology |
- Stock Market
- Insiders
- Alan B. Glassberg
















